{"id":"NCT02472145","sponsor":"Janssen Research & Development, LLC","briefTitle":"An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy","officialTitle":"A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-08-04","primaryCompletion":"2018-01-25","completion":"2018-01-25","firstPosted":"2015-06-15","resultsPosted":"2019-02-28","lastUpdate":"2019-03-19"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia, Myeloid, Acute"],"interventions":[{"type":"DRUG","name":"Decitabine 20 mg/m^2","otherNames":["DACOGEN"]},{"type":"DRUG","name":"Talacotuzumab 9 mg/kg","otherNames":["CSL362"]}],"arms":[{"label":"Decitabine plus Talacotuzumab","type":"EXPERIMENTAL"},{"label":"Decitabine","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of study Part A is to assess the safety of talacotuzumab (formerly CSL362) monotherapy and confirm the recommended Phase 2 dose (RP2D) in participants with acute myeloid leukemia (AML) for whom experimental therapy is appropriate. The primary objective of study Part B are to assess complete response (CR) rate and overall survival (OS) in participants with AML who are not eligible for intense induction chemotherapy and who are randomly assigned to receive decitabine plus talacotuzumab at the RP2D or decitabine alone.","primaryOutcome":{"measure":"Part B: Percentage of Participants Who Achieved Complete Response (Complete Response Rate) Based on Investigator Assessment","timeFrame":"Approximately up to 2.5 years","effectByArm":[{"arm":"Part B: Decitabine (Alone)","deltaMin":11.9,"sd":null},{"arm":"Part B: Decitabine + JNJ-56022473","deltaMin":16.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4747"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":81,"countries":["United States","Australia","Belgium","France","Germany","Israel","Poland","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["34521609"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":10},"commonTop":["Thrombocytopenia","Anaemia","Neutropenia","Pyrexia","Constipation"]}}